Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
- 27 February 2023
- journal article
- review article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 1999-2011
Abstract
Various biological disease-modifying anti-rheumatic drugs (bDMARDs) have been applied for treating axial spondyloarthritis (axSpA). However, there is a glaring absence of a bibliometric analysis on bDMARDs against axSpA. Articles related to use of bDMARDs in treating axSpA published from 2004 to 2022 were searched from the Web of Science Core Collection. VOS viewer 1.6.18 and CiteSpace 6.1.R2 were used to analyze and visualize the quantity and citations of publications, as well as to identify “research hotspots” and trends in this field. BibExcel version 1.0.0 and gCLUTO version 1.0 were used to build matrices for bi-clustering analysis. A total of 2546 articles referring to bDMARDs for treatment of axSpA were included in this bibliometric analysis. Overall, the number of publications has been increasing steadily annually. The USA (23.21%, 591 publications) ranked first with the largest output of papers, followed by Germany, and the Netherlands. Rheumazentrum Ruhrgebiet ranked first as the most frequent publisher (119 articles). Annals of the Rheumatic Diseases published the most documents (6.76%, 172 publications) in this field. The predominant hotspots have been “tuberculosis,” “IL-17,” and “quality of life” in the field until 2020. Since 2015, “biosimilar pharmaceuticals” has retained the popularity. Current research hotspots are “spinal radiographic progression,” Janus kinase (JAK) inhibitors, and adverse events (AEs). Machine learning has become popular gradually. Globally, there has been a steady increase in the number of studies on bDMARDs use against axSpA. JAK inhibitors, spinal radiographic progression, biosimilar pharmaceuticals, and AEs are current research hotspots. Machine learning is emerging research hotspots and trends in this field.Keywords
Funding Information
- China-Japan Friendship Hospital (ZRJY2021-QM14)
- National High Level Hospital Clinical Research Funding (2022-NHLHCRF-LX-02)
- Capital’s Funds for Health Improvement and Research (2020-4-40610)
- National Regional Traditional Chinese Medicine (Specialty) Treatment Center Project (2019-ZX-006)
- National Key Clinical Specialty Building Project (2011-ZDZK-001)
This publication has 50 references indexed in Scilit:
- Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyAnnals of the Rheumatic Diseases, 2014
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Annals of the Rheumatic Diseases, 2013
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2011
- ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient versionAnnals of the Rheumatic Diseases, 2009
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnnals of the Rheumatic Diseases, 2009
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritisAnnals of the Rheumatic Diseases, 2009
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trialArthritis & Rheumatism, 2003
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984